Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Clinical Oncology: Case Reports
Melody Cobleigh Author
Subjects of specialization
Affiliation
Breast cancer biology and treatment, clinical trials, cancer oncology, Carcinogenesis
Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, USA
Biography
Melody A. Cobleigh, MD’s national service has included leadership positions on the Breast Cancer Committee of the American Society of Clinical Oncology, the Patient Advocacy Committee, the Health Services Research Committee and three terms on the editorial board of the Journal of Clinical Oncology. She currently serves on the core committee of NRG, an international clinical trial network. With a primary clinical and research interest in breast cancer, Cobleigh has published articles on treatment of breast cancer using monoclonal antibody, endocrine, retinoid, antiangiogenesis, antisense, immunotherapy, tumor vaccine and chemotherapies.
Publications
Case Report Open Access
Extreme Response to Immunotherapy in an Estrogen Receptor Positive Breast Cancer: A Case Report
Author(s): Rebecca Fitzpatrick and Melody Cobleigh
Introduction: Currently, immune checkpoint inhibitors are not approved by the FDA for HR-positive breast cancer, although an extreme response was seen in the case below.
Case: The patient is a 72 year old, woman who was diagnosed in 1996, at age 48, with stage T2N2aM0, ER-positive infiltrating ductal cancer in her left breast. She completed 4 cycles of doxorubicin and cyclophosphamide and she received adjuvant tamoxifen, until 2004, then was switched to letrozole, which was completed in April, 2011, thus completing 15 years of endocrine treatment. She recurred in 2017 with pleomorphic invasive lobular carcinoma, ER 5%, PR 0%, and HER2 not amplified by FISH. She eventually progressed through 5 lines of treatment. The 2/2019 biopsy spec... view more»
Social Media
Google Scholars / Researchers Sites
